200 related articles for article (PubMed ID: 21649581)
1. mTOR inhibitors: facing new challenges ahead.
Mavrommati I; Maffucci T
Curr Med Chem; 2011; 18(18):2743-62. PubMed ID: 21649581
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of mTOR in aging and cancer.
Zhavoronkov A
Oncotarget; 2015 Dec; 6(42):45010-1. PubMed ID: 26942715
[No Abstract] [Full Text] [Related]
3. Current treatment strategies for inhibiting mTOR in cancer.
Chiarini F; Evangelisti C; McCubrey JA; Martelli AM
Trends Pharmacol Sci; 2015 Feb; 36(2):124-35. PubMed ID: 25497227
[TBL] [Abstract][Full Text] [Related]
4. Current and future directions in mammalian target of rapamycin inhibitors development.
Fasolo A; Sessa C
Expert Opin Investig Drugs; 2011 Mar; 20(3):381-94. PubMed ID: 21299441
[TBL] [Abstract][Full Text] [Related]
5. Targeting mTOR signaling pathway in ovarian cancer.
Mabuchi S; Hisamatsu T; Kimura T
Curr Med Chem; 2011; 18(19):2960-8. PubMed ID: 21651485
[TBL] [Abstract][Full Text] [Related]
6. mTOR pathway inhibitors in cancer therapy: moving past rapamycin.
Wacheck V
Pharmacogenomics; 2010 Sep; 11(9):1189-91. PubMed ID: 20860456
[No Abstract] [Full Text] [Related]
7. mTOR kinase inhibitors as a treatment strategy in hematological malignancies.
Grzybowska-Izydorczyk O; Smolewski P
Future Med Chem; 2012 Mar; 4(4):487-504. PubMed ID: 22416776
[TBL] [Abstract][Full Text] [Related]
8. Revisiting mTOR inhibitors as anticancer agents.
Teng QX; Ashar YV; Gupta P; Gadee E; Fan YF; Reznik SE; Wurpel JND; Chen ZS
Drug Discov Today; 2019 Oct; 24(10):2086-2095. PubMed ID: 31173912
[TBL] [Abstract][Full Text] [Related]
9. Targeting the mTOR kinase domain: the second generation of mTOR inhibitors.
Zhang YJ; Duan Y; Zheng XF
Drug Discov Today; 2011 Apr; 16(7-8):325-31. PubMed ID: 21333749
[TBL] [Abstract][Full Text] [Related]
10. Present and future of PI3K pathway inhibition in cancer: perspectives and limitations.
Ciraolo E; Morello F; Hirsch E
Curr Med Chem; 2011; 18(18):2674-85. PubMed ID: 21649577
[TBL] [Abstract][Full Text] [Related]
11. mTOR kinase inhibitors as potential cancer therapeutic drugs.
Sun SY
Cancer Lett; 2013 Oct; 340(1):1-8. PubMed ID: 23792225
[TBL] [Abstract][Full Text] [Related]
12. [mTOR inhibitor].
Muro K
Gan To Kagaku Ryoho; 2011 Jan; 38(1):7-11. PubMed ID: 21368454
[TBL] [Abstract][Full Text] [Related]
13. Targeting the mTOR pathway in tumor malignancy.
Cheng H; Walls M; Baxi SM; Yin MJ
Curr Cancer Drug Targets; 2013 Mar; 13(3):267-77. PubMed ID: 23297825
[TBL] [Abstract][Full Text] [Related]
14. Targeting mTOR and Metabolism in Cancer: Lessons and Innovations.
Magaway C; Kim E; Jacinto E
Cells; 2019 Dec; 8(12):. PubMed ID: 31817676
[TBL] [Abstract][Full Text] [Related]
15. mTOR signaling pathway and mTOR inhibitors in cancer therapy.
Gomez-Pinillos A; Ferrari AC
Hematol Oncol Clin North Am; 2012 Jun; 26(3):483-505, vii. PubMed ID: 22520976
[TBL] [Abstract][Full Text] [Related]
16. The mTOR Signaling Pathway and mTOR Inhibitors in Cancer: Next-generation Inhibitors and Approaches.
Ihlamur M; Akgul B; Zengin Y; Korkut ŞV; Kelleci K; Abamor EŞ
Curr Mol Med; 2024; 24(4):478-494. PubMed ID: 37165594
[TBL] [Abstract][Full Text] [Related]
17. Targeting mTOR for cancer therapy.
Hua H; Kong Q; Zhang H; Wang J; Luo T; Jiang Y
J Hematol Oncol; 2019 Jul; 12(1):71. PubMed ID: 31277692
[TBL] [Abstract][Full Text] [Related]
18. Updates of mTOR inhibitors.
Zhou H; Luo Y; Huang S
Anticancer Agents Med Chem; 2010 Sep; 10(7):571-81. PubMed ID: 20812900
[TBL] [Abstract][Full Text] [Related]
19. Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway.
Smolewski P
Anticancer Drugs; 2006 Jun; 17(5):487-94. PubMed ID: 16702804
[TBL] [Abstract][Full Text] [Related]
20. mTOR in Lung Neoplasms.
Krencz I; Sebestyen A; Khoor A
Pathol Oncol Res; 2020 Jan; 26(1):35-48. PubMed ID: 32016810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
